NCT03775265 2026-03-18
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT04660344 2026-02-13
IMvigor011
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT04338269 2025-04-04
CONTACT-03
Hoffmann-La Roche
Phase 3 Completed
NCT02807636 2025-02-24
IMvigor130
Hoffmann-La Roche
Phase 3 Completed
NCT04637594 2025-01-15
IMAGINE
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03016312 2024-08-09
IMbassador250
Hoffmann-La Roche
Phase 3 Completed
NCT03024996 2023-08-03
IMmotion010
Hoffmann-La Roche
Phase 3 Terminated
NCT02450331 2023-06-18
IMvigor010
Hoffmann-La Roche
Phase 3 Terminated
NCT02420821 2023-01-30
IMmotion151
Hoffmann-La Roche
Phase 3 Completed
NCT02302807 2019-08-01
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Hoffmann-La Roche
Phase 3 Completed
NCT03693573 2018-11-15
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
Hoffmann-La Roche
Phase 3 Withdrawn